You are here

Article Text

Article menu
Download PDFPDF
Meeting summary
Report from the European Society of Gynaecological Oncology (ESGO) 2020 State-of-the-Art Virtual Meeting
  1. Zoia Razumova1,
  2. Nicolò Bizzarri2,
  3. Joanna Kacperczyk-Bartnik3,
  4. Andrei Pletnev4,
  5. Antonio Gonzalez Martin5 and
  6. Jan Persson6,7
  1. 1 Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
  2. 2 Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, UOC Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
  3. 3 2nd Department of Obstetrics and Gynaecology, Medical University of Warsaw, Warsaw, Poland
  4. 4 Department of Gynaecological Oncology, N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus
  5. 5 Department of Medical Oncology, Clinica Universidad de Navarra, Madrid, Spain
  6. 6 Department of Obstetrics and Gynaecology, Skåne University Hospital, Lund, Sweden
  7. 7 Department of Clinical Sciences, Faculty of Medicine at Lund University, Lund, Sweden
  1. Correspondence to Dr Zoia Razumova, Department of Women's and Children's Health, Karolinska Institutet, 171 77 Stockholm, Sweden; zoia.razumova{at}ki.se

Abstract

This is a report from the European Society of Gynaecological Oncology State-of-the-Art Virtual Meeting held December 14–16, 2020. The unique 3-day conference offered comprehensive state-of-the-art summaries on the major advances in the treatment of different types of gynecological cancers. Sessions opened with a case presentation followed by a keynote lecture and interactive debates with opinion leaders in the field. The speakers also presented scientific reviews on the clinical trial landscape in collaboration with the European Network of Gynecological Oncological Trial (ENGOT) groups. In addition, the new ESGO-ESRTO-ESP endometrial cancer guidelines were officially presented in public. This paper describes the key information and latest studies that were presented for the first time at the conference.

  • cervical cancer
  • ovarian cancer
  • uterine cancer
  • vulvar and vaginal cancer
  • miscellaneous

https://doi.org/10.1136/ijgc-2021-002577

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors ZR: conceptualization, data curation, methodology, writing original draft, review, and editing. NB: conceptualization, data curation, methodology, writing original draft. JK-B: conceptualization, data curation, methodology, writing original draft. AP: conceptualization, data curation, methodology, writing original draft. AGM: conceptualization, methodology, review, and editing. JP: conceptualization, methodology, review, and editing.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.